Plain-English translation of NCT05835986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new medication called , given as an injection under the skin, in people with systemic lupus erythematosus (lupus). The trial is designed to understand whether this medication is safe to use, how the body handles it, and whether it helps reduce lupus disease activity.
Lupus is a serious autoimmune disease that can affect many parts of the body, and current treatments don't work well enough for everyone. Researchers are testing this medication to see if it offers a new treatment option for people who need better disease control.
In Part 1, you would receive a single injection of the medication under your skin. In Part 2, you would receive multiple injections over several days at increasing doses. Throughout the study, you would have blood tests and clinic visits so researchers can monitor your safety, how your body responds to the medication, and whether your lupus symptoms improve.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
Colombia
France